56161-89-8

Usage

Uses

Used in Over-the-Counter Products:
METHYL P-AMINOETHYLBENZOATE HCL is used as a local anesthetic for [providing temporary relief from pain and discomfort] in over-the-counter products such as sore throat sprays, teething gels for infants, and creams for skin irritations.
Used in Medical Applications:
METHYL P-AMINOETHYLBENZOATE HCL is used as a local anesthetic for [numbing a specific area before minor medical procedures], ensuring patient comfort and minimizing pain during the process.
However, it is important to note that METHYL P-AMINOETHYLBENZOATE HCL can produce side effects like methemoglobinemia, a serious disorder that significantly reduces the amount of oxygen in the blood, particularly in infants or young children. This highlights the need for cautious use and monitoring when administering METHYL P-AMINOETHYLBENZOATE HCL.

InChI:InChI=1/C10H13NO2.ClH/c1-13-10(12)9-4-2-8(3-5-9)6-7-11;/h2-5H,6-7,11H2,1H3;1H

Upstream product

• 67-56-1 methanol 
• 1199-69-5 4-(2-aminoethyl)benzoic acid 
• 1175530-38-7 4-((hydroxyiminomethyl)methyl)benzoic acid methyl ester 
• 60531-36-4 4-(2-amino-ethyl)-benzoic acid hydrochloride 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 

Downstream Products

• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 958891-65-1 benzyl 4-(methoxycarbonyl)phenethylcarbamate 
• 1252657-61-6 methyl 4-[2-({[4-(2-tert-butylphenyl)piperazin-1-yl](oxo)acetyl}amino)ethyl]benzoate 
• 421551-75-9 tert-butyl (4-formylphenethyl)carbamate 
• 421551-76-0 tert-butyl N-{2-[4-(hydroxymethyl)phenyl]ethyl}carbamate 
• 1057491-40-3 tert-butyl 4-((3-morpholinopropylamino)methyl)-phenethylcarbamate 
• 1057854-78-0 (S)-1-(4-(2-aminoethyl)benzyl)-1-(3-morpholinopropyl)-3-(1-(naphthalen-1-yl)ethyl)urea 
• 1057454-66-6 (S)-1-(4-(2-(pyrimidin-2-ylamino)ethyl)benzyl)-1-(3-morpholinopropyl)-3-(1-(naphthalen-1-yl)ethyl)urea 
• 1057454-59-7 (S)-1-(4-(2-(benzylamino)ethyl)benzyl)-1-(3-morpholinopropyl)-3-(1-(naphthalen-1-yl)ethyl)urea 
• 1057454-45-1 (S)-tert-butyl 4-((1-(3-morpholinopropyl)-3-(1-(naphthalen-1-yl)ethyl)ureido)methyl)phenethylcarbamate 
• 1057454-38-2 (S)-1-(4-(2-(phenylsulfonamido)ethyl)benzyl)-1-(3-morpholinopropyl)-3-(1-(naphthalen-1-yl)ethyl)urea 

Relevant academic research and scientific papers

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

ASPARAGINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of them, pharmaceutical compositions comprising them, methods of preparation thereof, intermediate compounds useful for the preparation thereof, and methods of treatment or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using these. (A) (I)

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure–activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.

PYRIDINIUM SALTS AND USES THEREOF

A 1,3,5-trisubstituted pyridinium salt of general formula I (I) wherein Xn- is a counterion in which n is an integer from 1 to 4; wherein R2 and R3 are each independently a substituent group comprising Ar, wherein Ar is an aryl or heteroaryl group, which is substituted or unsubstituted; wherein R1 is a substituent group linked to the quarternary nitrogen of the pyridinium ring by an aliphatic carbon; and wherein, when R1 is benzyl, R2 and R3 are not both phenyl, 3-MeO phenyl, 4-Br phenyl, 3-CF3 phenyl, 2-Me phenyl or 4-(4-tert BuPh) phenyl; when R1 is 3-MeO phenethyl, R2 and R3 are not both 3-MeO phenyl; and when R1 is dimethoxyphenethyl, R2 and R3 are not both phenyl.

Occupying a flat subpocket in a tRNA-modifying enzyme with ordered or disordered side chains: Favorable or unfavorable for binding?

Small-molecule ligands binding with partial disorder or enhanced residual mobility are usually assumed as unfavorable with respect to their binding properties. Considering thermodynamics, disorder or residual mobility is entropically favorable and contrib

HISTONE DEACETYLASE INHIBITORS

Provided herein are isoform selective histone deacetylase inhibitors of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds are isoform selective inhibitors of HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as cancer, malignant tumors, autoimmune diseases, skin diseases, fungal infections, protozoal infections, HIV, inflammation and CNS disorders.

NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE

The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

ANTIVIRAL COMPOUNDS AND USE THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.

BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

"TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES"

We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases.